Cancer Research Aziza Shad  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Armeanu, S.
Right arrow Articles by Bitzer, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Armeanu, S.
Right arrow Articles by Bitzer, M.
[Cancer Research 63, 2369-2372, May 15, 2003]
© 2003 American Association for Cancer Research


Advances in Brief

Adenoviral Gene Transfer of Tumor Necrosis Factor-related Apoptosis-Inducing Ligand Overcomes an Impaired Response of Hepatoma Cells but Causes Severe Apoptosis in Primary Human Hepatocytes1

Sorin Armeanu2, Ulrich M. Lauer, Irina Smirnow, Martin Schenk, Thomas S. Weiss, Michael Gregor and Michael Bitzer2,3

Medical University Clinic, Department of Internal Medicine I [S. A., U. M. L., I. S., M. G., M. B], Surgical University Clinic, Department of General Surgery [M. S.], 72076 Tübingen, and Center for Liver Cell Research, University Hospital, 93042 Regensburg [T. S. W.], Germany

Ligands of the tumor necrosis factor family play key roles in liver pathogenesis. The ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is unique, because it is thought to be nontoxic to normal cells while killing a broad range of tumor cells. However, hepatocellular carcinoma is considered resistant to soluble TRAIL treatment. Therefore, a direct gene transfer of TRAIL to malignant cells is part of an alternative delivery strategy. We show that an adenoviral gene transfer (Ad-TRAIL) overcomes an impaired response of hepatocellular carcinoma cell lines to soluble TRAIL, but the transduction of primary human hepatocytes revealed a high number of apoptotic cells. Our data imply that Ad-TRAIL administration in vivo must either be restricted to tumor tissue or controlled by a tumor-specific promoter to avoid severe liver damage in human trials.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
C. Wang, R. Qi, N. Li, Z. Wang, H. An, Q. Zhang, Y. Yu, and X. Cao
Notch1 Signaling Sensitizes Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Human Hepatocellular Carcinoma Cells by Inhibiting Akt/Hdm2-mediated p53 Degradation and Up-regulating p53-dependent DR5 Expression
J. Biol. Chem., June 12, 2009; 284(24): 16183 - 16190.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
S R Mucha, A Rizzani, A L Gerbes, P Camaj, W E Thasler, C J Bruns, S T Eichhorst, E Gallmeier, F T Kolligs, B Goke, et al.
JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand
Gut, May 1, 2009; 58(5): 688 - 698.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Carlo-Stella, C. Lavazza, A. Locatelli, L. Vigano, A. M. Gianni, and L. Gianni
Targeting TRAIL Agonistic Receptors for Cancer Therapy
Clin. Cancer Res., April 15, 2007; 13(8): 2313 - 2317.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
K. Miller-Jensen, K. A. Janes, Y.-L. Wong, L. G. Griffith, and D. A. Lauffenburger
Adenoviral vector saturates Akt pro-survival signaling and blocks insulin-mediated rescue of tumor-necrosis-factor-induced apoptosis
J. Cell Sci., September 15, 2006; 119(18): 3788 - 3798.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. Jacob, J. Davis, H. Zhu, L. Zhang, F. Teraishi, S. Wu, F. C. Marini III, and B. Fang
Suppressing Orthotopic Pancreatic Tumor Growth with a Fiber-Modified Adenovector Expressing the TRAIL Gene from the Human Telomerase Reverse Transcriptase Promoter
Clin. Cancer Res., May 15, 2004; 10(10): 3535 - 3541.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.